Anthem Biosciences Reports Audited Consolidated Financial Results for FY26 and Q4FY26
Anthem Biosciences Limited, an innovation-driven Contract Research, Development and Manufacturing Organization (CRDMO), announced its Audited Consolidated Financial Results for the quarter and year ended March 31, 2026.The company reported significant growth across key segments, with consolidated revenue from operations for the full year reaching ₹21,243 Mn. For the quarter ended March 31, 2026, consolidated revenue stood at ₹6,109 Mn.
Financial Highlights: FY26 vs. Q4FY26
The financial performance data for the full year (FY26) and the fourth quarter (Q4FY26) showed robust growth compared to the previous year (FY25 and Q4FY25).| Particulars (₹ Mn) | Q4FY26 | Q4FY25 | YoY Change (%) | FY26 | FY25 | YoY Change (%) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 6,109 | 4,832 | 26.4% | 21,243 | 18,446 | 15.2% |
| CRDMO | 5,128 | 3,923 | 30.7% | 17,727 | 15,061 | 17.7% |
| Specialty Ingredients | 981 | 909 | 7.9% | 3,516 | 3,385 | 3.9% |
| Other Income | 512 | 140 | 265.7% | 1,558 | 857 | 81.8% |
| Total Revenues | 6,622 | 4,973 | 33.2% | 22,801 | 19,303 | 18.1% |
| EBITDA | 3,184 | 2,092 | 52.2% | 9,896 | 7,566 | 30.8% |
| Profit after tax | 1,898 | 826 | 129.8% | 5,918 | 4,513 | 31.1% |
The CRDMO segment was a primary driver of growth, contributing ₹17,727 Mn in revenue for FY26, up 17.7% year over year, with Q4FY26 showing a 30.7% increase to ₹5,128 Mn. Specialty Ingredients delivered ₹3,516 Mn in consolidated revenue for the fiscal year.
Year-End Financial Performance (FY26)
The company reported key consolidated metrics for the year ended March 31, 2026:- Revenue from Operations: ₹21,243 Mn
- EBITDA: ₹9,896 Mn, maintaining an EBITDA margin of 43.4%.
- Profit after Tax (PAT): ₹5,918 Mn, with PAT margins at 26.0%.
- Exceptional Item: The net expense recognized for the exceptional item due to the new labour code impact was ₹244 Mn.
For the quarter alone, the figures were:
- Revenue from Operations: ₹6,109 Mn
- EBITDA: ₹3,184 Mn, achieving an EBITDA margin of 48.1%.
- PAT: ₹1,898 Mn, reflecting PAT margins of 28.7%.
Management Commentary
Ajay Bhardwaj, Chairman, MD and CEO, Anthem Biosciences Limited, noted that the company concluded the financial year 2025-26 on a strong note, citing Q4FY26 as its highest revenue quarter ever.He stated that the company delivered a Revenue growth of 26% Year over Year (YoY) for the quarter and 15% YoY for the financial year 2025-26. Mr. Bhardwaj attributed the expansion in profitability margins and revenue growth to the company's commitment to prudent cost management and focus on long-term value creation.
The CEO highlighted that EBITDA and PAT for the year grew by more than 30%, indicating strong operational performance. Anthem Biosciences maintained a net cash position of ₹13,743 Mn as of March 31, 2026.
ANTHEM Stock Price Movement
On Tuesday, Anthem Biosciences Limited shares shed 1.12% to settle at ₹787.35, falling from its previous close. The equity experienced significant trading activity, processing a total volume of 293,810 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.